Bevacizumab plus FOLFOX or FOLFIRI regimens on patients with unresectable liver-only metastases of metastatic colorectal cancer

Bevacizumab plus FOLFOX or FOLFIRI regimens on patients with unresectable liver-only metastases of metastatic colorectal cancer

Background: The present study was aimed to evaluate the efficacy and safety of at least three cycles of Bevacizumab in combination with chemotherapy regimens, FOLFIRI or FOLFOX to treat liver metastatic colorectal cancer and improved response rates in these patients. Materials and Methods: In this...

Full description

Bibliographic Details
Main Authors: Valiollah Mehrzad, Mahnaz Roayaei, Mohammad Saleh Peikar, Elham Nouranian, Fariborz Mokarian, Mohsen Khani, Somaieh Farzannia
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2016-01-01
Series:Advanced Biomedical Research
Subjects:
Bevacizumab
colorectal cancer
FOLFIRI
FOLFOX
liver metastasis
Online Access:http://www.advbiores.net/article.asp?issn=2277-9175;year=2016;volume=5;issue=1;spage=10;epage=10;aulast=Mehrzad

Internet

http://www.advbiores.net/article.asp?issn=2277-9175;year=2016;volume=5;issue=1;spage=10;epage=10;aulast=Mehrzad

Similar Items